Market capitalization | $541.84m |
Enterprise Value | $431.20m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.75 |
P/S ratio (TTM) P/S ratio | 3.45 |
P/B ratio (TTM) P/B ratio | 3.27 |
Revenue growth (TTM) Revenue growth | 18.98% |
Revenue (TTM) Revenue | $157.04m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
9 Analysts have issued a SI-BONE, Inc. forecast:
9 Analysts have issued a SI-BONE, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 157 157 |
19%
19%
|
|
Gross Profit | 122 122 |
13%
13%
|
|
EBITDA | -38 -38 |
8%
8%
|
EBIT (Operating Income) EBIT | -42 -42 |
8%
8%
|
Net Profit | -37 -37 |
14%
14%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SI-BONE, Inc. is a medical device company. It focuses on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy. The firm's product, iFuse, seeks to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in San Jose, CA.
Head office | United States |
CEO | Laura Francis |
Employees | 344 |
Founded | 2008 |
Website | www.si-bone.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.